Supplemental material
OncoImmunology
Volume 8, 2019 - Issue 11
Original Research
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
, , , , 
, , , , , , , , , , , , , & show all
Ralf BergmannDepartment of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germanyhttps://orcid.org/0000-0002-8733-4286
https://orcid.org/0000-0002-8733-4286, , , , , , , , , Jens PietzschDepartment of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany;Department of Chemistry and Food Chemistry, School of Science, TU Dresden, Dresden, Germanyhttps://orcid.org/0000-0002-1610-1493
https://orcid.org/0000-0002-1610-1493, , , , & show allRelated Research Data
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Source:
Springer Science and Business Media LLC
Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses
Source:
Elsevier BV
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Source:
American Association for the Advancement of Science (AAAS)
Globocan 2012
Source:
Wiley
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
Source:
Society of Nuclear Medicine
Theranostic CAR T cell targeting: A brief review.
Source:
Wiley
Redirection of genetically engineered CAR-T cells using bifunctional small molecules.
Source:
American Chemical Society (ACS)
Conventional CARs versus modular CARs
Source:
Springer Science and Business Media LLC
The Principles of Engineering Immune Cells to Treat Cancer
Source:
Elsevier BV
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
Source:
American Chemical Society (ACS)
Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
Source:
American Chemical Society (ACS)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Source:
Springer Science and Business Media LLC
Localized Prostate Cancer
Source:
Massachusetts Medical Society
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
Source:
Public Library of Science (PLoS)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Source:
Elsevier BV
Prostate stem cell antigen: A prospective therapeutic and diagnostic target
Source:
Elsevier BV
Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Source:
Springer Science and Business Media LLC
Cancer gene therapy with T cell receptors and chimeric antigen receptors
Source:
Elsevier BV
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
Source:
Informa UK Limited
A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
Source:
American Association for Cancer Research (AACR)
Bispecific abs for Treatment of PCa
Source:
Wiley
Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.
Source:
Elsevier BV
Prostate cancer as a model for tumour immunotherapy
Source:
Springer Science and Business Media LLC
CAR-T cells are serial killers.
Source:
Informa UK Limited
Current status of theranostics in prostate cancer.
Source:
Springer Science and Business Media LLC
Ab-Based Dual-Targeting of PCa
Source:
Wiley
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
Source:
Future Medicine Ltd
Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)
Source:
AME Publishing Company
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Source:
Proceedings of the National Academy of Sciences
Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8 + and CD4 + T Cells
Source:
The American Association of Immunologists
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
Source:
Springer Science and Business Media LLC
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
Source:
Springer Science and Business Media LLC
CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies.
Source:
S. Karger AG
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Source:
Society of Nuclear Medicine
A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer
Source:
Springer Science and Business Media LLC
Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience
Source:
Springer Science and Business Media LLC
68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging
Source:
American Chemical Society (ACS)
Natural history of progression after PSA elevation following radical prostatectomy.
Source:
American Medical Association (AMA)
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
Source:
Springer Science and Business Media LLC
Linking provided by
